Common Shares Outstanding: The number of class A shares currently held by investors.
Relmada Therapeutics, Inc. (RLMD) had Common Shares Outstanding of 106.67M for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
-- |
|
$-12.91M |
|
-- |
|
-- |
|
$15.01M |
|
$-15.01M |
|
$2.10M |
|
$-12.91M |
|
$-12.71M |
|
$-12.91M |
|
$-12.91M |
|
$-12.91M |
|
$-12.71M |
|
$-15.01M |
|
$-15.01M |
|
112.38M |
|
112.38M |
|
$-0.11 |
|
$-0.11 |
|
| Balance Sheet Financials | |
$219.04M |
|
-- |
|
$0.02M |
|
$219.06M |
|
$7.42M |
|
-- |
|
$5.08M |
|
$12.50M |
|
$206.56M |
|
$206.56M |
|
$206.56M |
|
|
Common Shares Outstanding |
106.67M |
| Cash Flow Statement Financials | |
$-24.67M |
|
$-117.64M |
|
$150.15M |
|
$3.50M |
|
$11.33M |
|
$7.84M |
|
$5.88M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
29.52 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-24.67M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-6.25% |
|
-6.25% |
|
-5.90% |
|
-6.25% |
|
$1.94 |
|
$-0.22 |
|
$-0.22 |
|